


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sbpgroup.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT

**LATEST RESEARCH DATA ON TQF6422 “ACTRII A/B MONOCLONAL ANTIBODY”
PRESENTED AT ECO 2026**

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that preclinical research data for TQF6422 “ActRII A/B Monoclonal Antibody”, an innovative drug independently developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (“**CTTQ**”), a subsidiary of the Company, has been presented at European Congress on Obesity 2026 (ECO).

TQF6422 is a fully human monoclonal antibody targeting ActRII A/B. By specifically binding to the ActRII A/B receptors and blocking transduction of ligand-mediated signaling involving Activin or Myostatin, it promotes skeletal muscle growth while enhancing lipolysis, thereby achieving the dual effect of fat loss and muscle gain.

Abstract Title:

TQ-Im-10: A Fully Human ActRII A/B Antibody Improves Weight Loss Quality by Preserving Lean Mass and Enhancing Fat Reduction

Preclinical Data ^[1]:

TQF6422 exhibits more than 10-fold higher in vitro activity compared to similar products. In various in vivo animal pharmacodynamic models, the product demonstrates superior fat reduction and lean mass preservation, while achieving therapeutic effects at lower doses. In combination with semaglutide, TQF6422 exhibits significant synergistic effects. In an obese monkey model, compared with semaglutide monotherapy, the combination regimen resulted in a 1.5- to 2-fold increase in fat loss, a 72–85% improvement in lean body mass preservation, and fat loss accounting for 93% of total weight loss.

Furthermore, TQF6422 has a significantly prolonged half-life, supporting longer dosing intervals and helping to improve patient adherence. Regarding safety, the drug was well tolerated by animals at all tested doses, with no drug-related adverse reactions observed, demonstrating excellent safety profiles.

The global obese and overweight population is growing rapidly and becoming younger, with a significant increase in the risk of complications such as diabetes and cardiovascular diseases. Although GLP-1 receptor agonists (GLP-1RAs), which are currently widely applied in clinical practice, can achieve a 15–21% reduction in body weight, as much as 20–40% of this loss is attributable to the loss of lean body mass (muscle mass)^[2], which in turn leads to a decrease in basal metabolic rate, reduced insulin sensitivity and an increased risk of fractures^[3]. Consequently, “preventing muscle loss and achieving high-quality weight loss” has become the core development focus for the next generation of weight-loss drugs.

Currently, no ActRII A/B monoclonal antibodies have been approved for marketing globally. The Group expects to submit a clinical trial application for its independently developed TQF6422 in the near future. With its superior efficacy, extended half-life and good safety profile, this product is poised to become an ideal candidate for a new generation of high-quality weight loss and long-term efficacy maintenance. Furthermore, the Group has established a diverse portfolio of innovative candidates in the weight loss sector: HJY-10 (INHBE siRNA) is currently progressing toward clinical trial application, while TQF3250 (oral GLP-1RA) has received clinical trial approval for weight loss and diabetes indications in both China and the United States. These candidates are expected to provide safer and longer-acting treatment options for hundreds of millions of obese and overweight patients worldwide in the future.

Sources:

- [1] TQ-Im-10: A Fully Human ActRII A/B Antibody Improves Weight Loss Quality by Preserving Lean Mass and Enhancing Fat Reduction, ECO 2026.
- [2] Bikou A et al., Expert Opin Pharmacother, 2024.
- [3] Argilés JM et al., J Am Med Dir Assoc, 2016.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 13 May 2026

As at the date of this announcement, the Board of the Company comprises six executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, and Mr. Tian Zhoushan, and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.